Biosimilars are not identical to their reference products due to the complex nature of biologics, which are produced using living systems. Unlike generic drugs, which have identical active ingredients to their branded counterparts, biosimilars are "similar" but not exact copies. This complexity raises unique challenges in confirming their safety and efficacy, necessitating a comprehensive evaluation process.
